Literature DB >> 17013947

Effect of drug-test interactions on length of hospital stay.

Ana Terleira1, Antonio Portolés, Aurora Rojas, Emilio Vargas.   

Abstract

PURPOSE: To evaluate the impact of drug-laboratory test interactions on the length of stay of hospitalised patients.
METHODS: Observational study of 404 discharges from the Internal Medicine Services of a tertiary hospital. Databases with information on general data, medication and tests performed were linked with the potential interactions described in the literature. This revealed the potential interactions between drugs and laboratory tests (PIDL) in each patient. Several linear regression models, adjusted for confounders, were performed to test the effect of both the number of PIDL and their influence on tests results (false positive/negative) on the length of stay.
RESULTS: A total of 19 741 PIDL were detected; 5954 could give rise to potential false positive (PFP) results and 8442 to potential false negative (PFN) ones. Each PFP was related to an increase of 0.051 days in stay duration (CI95% 0.001-0.102) and each PFN to 0.045 days (CI95% 0.008-0.081). Globally, 303 and 380 days of hospitalisation could be attributed to false positives and false negatives, which could account for 9.8% of the total stay of these patients.
CONCLUSIONS: These results show that the interactions between drugs and laboratory tests produce a statistically and clinically significant increase in the duration of hospital stay. Copyright (c) 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2007        PMID: 17013947     DOI: 10.1002/pds.1330

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  1 in total

1.  Gender differences, polypharmacy, and potential pharmacological interactions in the elderly.

Authors:  Carina Duarte Venturini; Paula Engroff; Luísa Scheer Ely; Luísa Faria de Araújo Zago; Guilherme Schroeter; Irenio Gomes; Geraldo Attilio De Carli; Fernanda Bueno Morrone
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.